Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06147037 · ClinicalTrials.gov registry record · Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

A Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
70
Enrollment target
15
Study locations

NCT06147037 is a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 70 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 15 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06147037, a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target
15
Study locations

Study Summary

This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC, GC, RCC).

Conditions Studied

Non-Small Cell Lung Cancer Advanced Solid Tumor Gastric Cancer Head and Neck Squamous Cell Carcinoma Renal Cell Carcinoma Pancreatic Ductal Adenocarcinoma Metastatic Colorectal Carcinoma

Interventions

  • DRUG FPI-2053
  • DRUG [111In]-FPI-2107
  • DRUG [225Ac]-FPI-2068

Study Locations (15)

California

  • Research Site - Irvine
  • Research Site - Palo Alto
  • Research Site - Santa Monica

Quebec

  • Research Site - Montreal
  • Research Site - Sherbrooke

Illinois

  • Research Site - Chicago

Massachusetts

  • Research Site - Boston

Missouri

  • Research Site - St Louis

Nebraska

  • Research Site - Omaha

Ohio

  • Research Site - Cleveland

Pennsylvania

  • Research Site - Pittsburgh

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-07-31
Est. Completion 2028-05-12
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06147037

The ClinicalTrials.gov registry entry for NCT06147037 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which FPI-2053 is the first listed.

NCT06147037 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Quebec, Illinois.

Frequently Asked Questions

What is clinical trial NCT06147037 about?

NCT06147037 is a clinical study titled "A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours". This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC...

What is the current status of trial NCT06147037?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-07-31. Estimated completion is 2028-05-12.

What conditions does trial NCT06147037 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma.

What interventions are being tested in trial NCT06147037?

The interventions under investigation include: FPI-2053 (DRUG), [111In]-FPI-2107 (DRUG), [225Ac]-FPI-2068 (DRUG).

Who is sponsoring clinical trial NCT06147037?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06147037 being conducted?

This trial has 15 study locations across California, Illinois, Massachusetts, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.